Compounds > sulphoraphene
Page last updated: 2024-12-11

sulphoraphene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

sulphoraphene: from radish; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6433206
CHEMBL ID49659
SCHEMBL ID2937706
MeSH IDM0449015

Synonyms (27)

Synonym
unii-nco9mc39io
nco9mc39io ,
sulphoraphene
isothiocyanic acid, 4-(methylsulfinyl)-3-butenyl ester
sulforaphene
1-butene, 4-isothiocyanato-1-(methylsulfinyl)-
raphanin
sulforaphen
4-isothiocyanato-1-(methylsulfinyl)-1-butene
sulphoraphen
CHEMBL49659
592-95-0
(e)-4-isothiocyanato-1-methylsulfinylbut-1-ene
AKOS006274434
SCHEMBL2937706
AC-34422
(1e)-4-isothiocyanato-1-methanesulfinylbut-1-ene
(r)-(e)-sulforaphene
s-sulforaphene ,
HY-N2450
F21504
Q7294040
1-methylsulfinylbutenyl isothiocyante
CS-0022676
MS-22937
(-)4-isothiocyanato-4r-(methylsulfinyl)-1-butene
AKOS040760048

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" This novel LC-MS-MS method shows satisfactory accuracy and precision and is sufficiently sensitive for the performance of pharmacokinetic studies in rats."( Development and validation of an LC-MS-MS method for the simultaneous determination of sulforaphane and its metabolites in rat plasma and its application in pharmacokinetic studies.
Khor, TO; Kong, AN; Lin, W; Nomeir, AA; Shen, G; Wang, H, )		0.13

Bioavailability

ExcerptReferenceRelevance
"The evaluation of the bioavailability of bioactive compounds from cruciferous foods is one challenge in the design of clinical trials for studying their functionality."( Bioavailability and new biomarkers of cruciferous sprouts consumption.
Baenas, N; García-Viguera, C; Moreno, DA; Suárez-Martínez, C, 2017)		0.46
" However, chemopreventive metabolites are typically inactive and have low bioavailability and poor host absorption."( Engineered commensal microbes for diet-mediated colorectal-cancer chemoprevention.
Chang, MW; Chua, KJ; Ho, CL; Kang, A; Lee, YS; Lim, KH; Ling, KL; Tan, HQ; Thiery, JP; Yew, WS, 2018)		0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Quinone oxidoreductaseMus musculus (house mouse)CD0.40000.20002.74219.8000AID163303
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID1418252Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418268Cell cycle arrest in human SMMC7721 cells assessed as accumulation at G0/G1 phase at 8 uM after 72 hrs by RNase/propidium iodide staining-based flow cytometric analysis (Rvb = 67.26%)2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418270Cell cycle arrest in human SMMC7721 cells assessed as accumulation at G2/M phase at 8 uM after 72 hrs by RNase/propidium iodide staining-based flow cytometric analysis (Rvb = 24.78%)2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418253Drug degradation in methanol after 10 hrs at 50 degC by HPLC analysis2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418250Antiproliferative activity against human A375 cells after 72 hrs by CCK8 assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418266Cell cycle arrest in human SMMC7721 cells assessed as accumulation at S phase at 4 uM after 72 hrs by RNase/propidium iodide staining-based flow cytometric analysis (Rvb = 7.96%)2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418247Antiproliferative activity against human SMMC7721 cells assessed as inhibition of cell proliferation at 32 uM after 72 hrs by CCK8 assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418261Induction of apoptosis in human SMMC7721 cells assessed as necrotic cells at 8 uM after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 6.76%)2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418245Antiproliferative activity against human A375 cells assessed as inhibition of cell proliferation at 32 uM after 72 hrs by CCK8 assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418244Antiproliferative activity against human A375 cells assessed as inhibition of cell proliferation at 16 uM after 72 hrs by CCK8 assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418256Inhibition of colony formation in human SMMC7721 cells at 2 to 8 uM after 7 days by crystal violet staining-based assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418265Cell cycle arrest in human SMMC7721 cells assessed as accumulation at G0/G1 phase at 4 uM after 72 hrs by RNase/propidium iodide staining-based flow cytometric analysis (Rvb = 67.26%)2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418249Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418267Cell cycle arrest in human SMMC7721 cells assessed as accumulation at G2/M phase at 4 uM after 72 hrs by RNase/propidium iodide staining-based flow cytometric analysis (Rvb = 24.78%)2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418248Antiproliferative activity against human SMMC7721 cells after 72 hrs by CCK8 assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID163303In vitro potency to induce quinone reductase activity in murine hepatoma cells was determined1994Journal of medicinal chemistry, Jan-07, Volume: 37, Issue:1
Design and synthesis of bifunctional isothiocyanate analogs of sulforaphane: correlation between structure and potency as inducers of anticarcinogenic detoxication enzymes.
AID1418264Induction of apoptosis in human SMMC7721 cells assessed as viable cells at 8 uM after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 91.92%)2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418262Induction of apoptosis in human SMMC7721 cells assessed as late apoptotic cells at 8 uM after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 0.62%)2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418258Induction of apoptosis in human SMMC7721 cells assessed as late apoptotic cells at 4 uM after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 0.62%)2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418246Antiproliferative activity against human SMMC7721 cells assessed as inhibition of cell proliferation at 16 uM after 72 hrs by CCK8 assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418263Induction of apoptosis in human SMMC7721 cells assessed as early apoptotic cells at 8 uM after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 0.70%)2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418259Induction of apoptosis in human SMMC7721 cells assessed as early apoptotic cells at 4 uM after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 0.70%)2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418260Induction of apoptosis in human SMMC7721 cells assessed as viable cells at 4 uM after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 91.92%)2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418257Induction of apoptosis in human SMMC7721 cells assessed as necrotic cells at 4 uM after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 6.76%)2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418251Antiproliferative activity against human HCT116 cells after 72 hrs by CCK8 assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
AID1418269Cell cycle arrest in human SMMC7721 cells assessed as accumulation at S phase at 8 uM after 72 hrs by RNase/propidium iodide staining-based flow cytometric analysis (Rvb = 7.96%)2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis and biological evaluation of novel carbamodithioates as anti-proliferative agents against human cancer cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (51)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (1.96)18.7374
1990's1 (1.96)18.2507
2000's3 (5.88)29.6817
2010's31 (60.78)24.3611
2020's15 (29.41)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 46.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index46.58 (24.57)
Research Supply Index3.97 (2.92)
Research Growth Index5.93 (4.65)
Search Engine Demand Index138.47 (26.88)
Search Engine Supply Index4.00 (0.95)

This Compound (46.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other52 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
methanol
Methanol: A colorless, flammable liquid used in the manufacture of FORMALDEHYDE and ACETIC ACID, in chemical synthesis, antifreeze, and as a solvent. Ingestion of methanol is toxic and may cause blindness.. primary alcohol : A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.. methanol : The primary alcohol that is the simplest aliphatic alcohol, comprising a methyl and an alcohol group.		2.1310alkyl alcohol;
one-carbon compound;
primary alcohol;
volatile organic compound		amphiprotic solvent;
Escherichia coli metabolite;
fuel;
human metabolite;
mouse metabolite;
Mycoplasma genitalium metabolite
3,3'-diindolylmethane
3,3'-diindolylmethane: anti-inflammatory from edible cruciferous vegetables; a cytochrome P-450 antagonist		3.0610indolesantineoplastic agent;
P450 inhibitor
vorinostat
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).		2.0310dicarboxylic acid diamide;
hydroxamic acid		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
sulforaphane
sulforaphane: from Cardaria draba L.. sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.		4.5380isothiocyanate;
sulfoxide		antineoplastic agent;
antioxidant;
EC 3.5.1.98 (histone deacetylase) inhibitor;
plant metabolite
acetonitrile
acetonitrile: RN given refers to unlabeled cpd. acetonitrile : A nitrile that is hydrogen cyanide in which the hydrogen has been replaced by a methyl group.		2.1310aliphatic nitrile;
volatile organic compound		EC 3.5.1.4 (amidase) inhibitor;
NMR chemical shift reference compound;
polar aprotic solvent
quinazolines
Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.		2.5320azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
phenethyl isothiocyanate
phenethyl isothiocyanate: a dietary liver aldehyde dehydrogenase inhibitor; promotes urinary bladder carcinoma. phenethyl isothiocyanate : An isothiocyanate having a phenethyl group attached to the nitrogen. It is a naturally occurring compound found in some cruciferous vegetables (e.g. watercress) and is known to possess anticancer properties.		2.4620isothiocyanateantineoplastic agent;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
metabolite
gold
Gold: A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.		2.2110copper group element atom;
elemental gold
etoposide
[no description available]		2.0510beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
chlorodiphenyl (54% chlorine)
Chlorodiphenyl (54% Chlorine): A mixture of polychlorinated biphenyls that induces hepatic microsomal UDP-glucuronyl transferase activity towards thyroxine.. Aroclor 1254 : A mixture of polychlorobiphenyls of unspecified composition, containing 54% chlorine (X = Cl or H).		2.0110
isothiocyanic acid
[no description available]		2.8630hydracid;
one-carbon compound
erucin
[no description available]		2.5320isothiocyanate
4-(methylthio)-3-butenyl isothiocyanate
4-(methylthio)-3-butenyl isothiocyanate: structure in first source		2.0610
lapatinib
[no description available]		2.5320furans;
organochlorine compound;
organofluorine compound;
quinazolines		antineoplastic agent;
tyrosine kinase inhibitor
trovafloxacin
glucoraphenin : A glucosinolic acid that consists of 1-thio-beta-D-glucopyranose attached to a 1-(methylsulfinyl)-5-[(sulfooxy)imino]pent-1-en-5-yl group at the anomeric sulfur.		3.0940
cysteine
Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.		2.1310cysteiniumfundamental metabolite
4-methylthio-3-butenyl glucosinolate
4-methylthio-3-butenyl glucosinolate: from Raphanus sativus sprouts; structure in first source		2.0610
glucoraphanin
glucoraphanin: precursor of sulforaphane. glucoraphanin : A thia-glucosinolic acid that is glucoerucin in which the sulfur atom of the methyl thioether group has been oxidised to the corresponding sulfoxide.		2.610sulfoxide;
thia-alkylglucosinolic acid
cytochrome c-t
Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.		2.1110
chitosan
[no description available]		2.2110
ConditionIndicatedRelationship StrengthStudiesTrials
Experimental Hepatoma
[description not available]		01.9810
Acne
[description not available]		04.0290
Innate Inflammatory Response
[description not available]		04.0290
Acne Vulgaris
A chronic disorder of the pilosebaceous apparatus associated with an increase in sebum secretion. It is characterized by open comedones (blackheads), closed comedones (whiteheads), and pustular nodules. The cause is unknown, but heredity and age are predisposing factors.		04.0290
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		04.0290
Acute Confusional Senile Dementia
[description not available]		03.5240
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		03.5760
Alzheimer Disease
A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)		03.5240
Rheumatoid Arthritis
[description not available]		02.610
Arthritis, Rheumatoid
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.		02.610
Bone Loss, Osteoclastic
[description not available]		02.610
Pericementitis
[description not available]		02.610
Periodontitis
Inflammation and loss of connective tissues supporting or surrounding the teeth. This may involve any part of the PERIODONTIUM. Periodontitis is currently classified by disease progression (CHRONIC PERIODONTITIS; AGGRESSIVE PERIODONTITIS) instead of age of onset. (From 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, American Academy of Periodontology)		02.610
Adenocarcinoma, Endometrioid
[description not available]		02.610
Epithelial Ovarian Cancer
[description not available]		02.610
Cancer of Ovary
[description not available]		02.6120
Carcinoma, Ovarian Epithelial
A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer.		02.610
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		02.6120
Carcinoma, Endometrioid
An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.		02.610
Disease Exacerbation
[description not available]		02.9430
Cancer of Esophagus
[description not available]		02.2510
Esophageal Neoplasms
Tumors or cancer of the ESOPHAGUS.		02.2510
Bone Cancer
[description not available]		02.2510
Osteogenic Sarcoma
[description not available]		02.2510
Bone Neoplasms
Tumors or cancer located in bone tissue or specific BONES.		02.2510
Osteosarcoma
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)		02.2510
Esophageal Squamous Cell Carcinoma
A carcinoma that originates usually from cells on the surface of the middle and lower third of the ESOPHAGUS. Tumor cells exhibit typical squamous morphology and form large polypoid lesions. Mutations in RNF6, LZTS1, TGFBR2, DEC1, and WWOX1 genes are associated with this cancer.		02.2510
Breast Cancer
[description not available]		03.2450
Breast Neoplasms
Tumors or cancer of the human BREAST.		03.2450
Germinoblastoma
[description not available]		02.1710
Benign Neoplasms
[description not available]		02.4820
Lymphoma
A general term for various neoplastic diseases of the lymphoid tissue.		02.1710
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.4820
Thyroid Cancer, Anaplastic
[description not available]		02.1710
Cancer of the Thyroid
[description not available]		02.1710
Thyroid Neoplasms
Tumors or cancer of the THYROID GLAND.		02.1710
Thyroid Carcinoma, Anaplastic
An aggressive THYROID GLAND malignancy which generally occurs in IODINE-deficient areas in people with previous thyroid pathology such as GOITER. It is associated with CELL DEDIFFERENTIATION of THYROID CARCINOMA (e.g., FOLLICULAR THYROID CARCINOMA; PAPILLARY THYROID CANCER). Typical initial presentation is a rapidly growing neck mass which upon metastasis is associated with DYSPHAGIA; NECK PAIN; bone pain; DYSPNEA; and NEUROLOGIC DEFICITS.		02.1710
Colorectal Cancer
[description not available]		02.5820
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		02.5820
Fish Diseases
Diseases of freshwater, marine, hatchery or aquarium fish. This term includes diseases of both teleosts (true fish) and elasmobranchs (sharks, rays and skates).		02.110
Infections, Rhabdoviridae
[description not available]		02.110
Cancer of Stomach
[description not available]		02.1310
Stomach Neoplasms
Tumors or cancer of the STOMACH.		02.1310
Cancer of Colon
[description not available]		02.1310
Colonic Neoplasms
Tumors or cancer of the COLON.		02.1310
Invasiveness, Neoplasm
[description not available]		02.1310
ER-Negative PR-Negative HER2-Negative Breast Cancer
[description not available]		02.1310
Triple Negative Breast Neoplasms
Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.		02.1310
Cancer of Lung
[description not available]		02.1310
Lung Neoplasms
Tumors or cancer of the LUNG.		02.1310
Cancer of Cervix
[description not available]		02.0510
Uterine Cervical Neoplasms
Tumors or cancer of the UTERINE CERVIX.		02.0510
Anasarca
[description not available]		02.0610
Myelopathy
[description not available]		02.0610
Injuries, Spinal Cord
[description not available]		02.0610
Edema
Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.		02.0610
Spinal Cord Diseases
Pathologic conditions which feature SPINAL CORD damage or dysfunction, including disorders involving the meninges and perimeningeal spaces surrounding the spinal cord. Traumatic injuries, vascular diseases, infections, and inflammatory/autoimmune processes may affect the spinal cord.		02.0610
Spinal Cord Injuries
Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).		02.0610